Ozanezumab is a monoclonal antibody designed to target Nogo-A (also known as RTN4), a protein that inhibits axonal growth and neural regeneration in the central nervous system. As a reference antibody, it is widely used in biological and biochemical research to detect and study Nogo-A protein expression and function. Its primary therapeutic application lies in the potential treatment of neurodegenerative diseases, particularly amyotrophic lateral sclerosis (ALS), and it has been investigated in clinical trials to assess its ability to slow disease progression and preserve motor function in ALS patients. By neutralizing Nogo-A, ozanezumab aims to promote neuronal plasticity and support the repair of damaged nerve pathways. Additionally, due to its mechanism of enhancing neural repair, ozanezumab holds research interest for other neurological conditions involving spinal cord injury or impaired nerve regeneration. It is commonly employed in laboratory techniques such as Western blot, immunofluorescence, and immunohistochemistry to investigate signaling pathways related to nerve recovery and evaluate targeted therapies.